Humacyte, Inc.
HUMA
$2.53
$0.135.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 26.52% | -34.24% | -71.01% | -57.49% | -263.22% |
| Total Depreciation and Amortization | -2.77% | -6.85% | -9.81% | -11.85% | -9.78% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -100.00% | -92.02% |
| Total Other Non-Cash Items | -273.14% | 89.78% | 718.09% | 855.09% | 126.98% |
| Change in Net Operating Assets | -321.88% | -95.27% | 336.99% | 534.27% | 332.15% |
| Cash from Operations | -21.17% | -33.85% | -23.75% | -4.79% | -15.55% |
| Capital Expenditure | 7.24% | 31.05% | 40.98% | 51.84% | 30.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -100.00% | -64.25% |
| Cash from Investing | -339.63% | -808.67% | -131.97% | -122.26% | -84.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 92.20% | 92.43% | 92.66% | 92.89% | -1,567.86% |
| Issuance of Common Stock | 125.50% | 16,656.54% | 7,158.97% | 5,943.01% | 6,614.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -96.69% | -42.33% | -46.32% | -50.11% | -- |
| Cash from Financing | 44.92% | 2,433.46% | 1,257.28% | 1,099.39% | 4,957.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.62% | 121.01% | 53.60% | 68.86% | 80.03% |